A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

I5Q-MC-CGAR -

The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Cluster Headaches
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
No
Enrollment Goal
165
Trial Dates
Jul 13, 2016 - Jan 21, 2021
How long will I be in the trial?
Your participation could last until approximately August 2020 and include monthly visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have participated in and completed either study CGAL or study CGAM

  • Participant must be reliable to follow all study procedures, keep all study visits, and be compliant with study requirements

  • Female participant must not be pregnant or nursing

Participants Must Not:

  • Participant must not be currently enrolled in or discontinued within the last 30 days from, a clinical trial involving any investigational drug or device (with the exception of study CGAL or study CGAM)

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.